Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-containing Regimens in HIV-infected Children Aged 4 Weeks to 2 Years—48-week Study Data-Reference-Cited by-同舟云学术

Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-containing Regimens in HIV-infected Children Aged 4 Weeks to 2 Years—48-week Study Data

Published:2014-01 Issue:1 Volume:33 Page:57-62
ISSN:0891-3668
Container-title:Pediatric Infectious Disease Journal
language:en
Short-container-title:

Author:

Cotton Mark,Cassim Haseena,Pavía-Ruz Noris,Garges Harmony P.,Perger Teodora,Ford Susan L.,Wire Mary Beth,Givens Naomi,Ross Lisa L.,Lou Yu,Sievers Jörg,Cheng Katharine

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Microbiology (medical),Pediatrics, Perinatology and Child Health

Reference12 articles.

1. The NEAT Study: A 48-week open-label study to compare the antiviral efficacy and safety of GW43908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.;Rodriguez-French;JAIDS,2004

2. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.;Gathe;AIDS,2004

3. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.;Perez-Elias;Antimicrob Agents Chemother,2009

4. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.;Sale;Antimicrob Agents Chemother,2002

5. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose co-administration to healthy volunteers.;Sadler;AIDS,2001

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution–Based Antiretroviral Therapy;AIDS Research and Human Retroviruses;2024-07-19

2. Pharmacokinetic Parameters of HIV‐1 Protease Inhibitors;ChemMedChem;2020-05-26

3. Advances in Pediatric Pharmacology, Therapeutics, and Toxicology;Advances in Pediatrics;2016-08

4. PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged ≥3 months to <6 years;Journal of the International AIDS Society;2015-01